A Clinical Study to Assess the Safety and Clinical Activity of Combination Treatment with Regorafenib and Milciclib in Liver Transplant Patients with Hepatocellular Carcinoma Recurrence
Latest Information Update: 18 Jun 2020
At a glance
- Drugs Milciclib (Primary) ; Regorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms MiHRCO
Most Recent Events
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 15 May 2020 New trial record
- 14 May 2020 According to a Tiziana Lifesciences media release, Prof. Erica Villa, M.D., is the site Investigator for this study at the Policlinico di Modena, Modena, Italy.